EXACT Sciences Corporation Offers Update On Cologuard’s® Early Launch Trajectory
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, more than 4,000 physicians wrote at least one prescription for the test and that as of December 31, the patient compliance rate was 74.6 percent. The Company estimates revenue during the fourth quarter of 2014 from Cologuard was approximately $1.5 million. Exact Sciences has not completed preparation of its financial statements for 2014 and this revenue estimate is based on preliminary data.
“We are pleased with the early launch trajectory of Cologuard,” said Kevin T. Conroy, chairman and chief executive of Exact Sciences. “In the short time since FDA approval, and particularly following the Medicare coverage determination, our sales force and marketing team generated a tremendous amount of interest in Cologuard from both doctors and patients.”
Help employers find you! Check out all the jobs and post your resume.
“We are pleased with the early launch trajectory of Cologuard,” said Kevin T. Conroy, chairman and chief executive of Exact Sciences. “In the short time since FDA approval, and particularly following the Medicare coverage determination, our sales force and marketing team generated a tremendous amount of interest in Cologuard from both doctors and patients.”
Help employers find you! Check out all the jobs and post your resume.